Jamil Khurram, the Chief Medical Officer (CMO) of Galectin Therapeutics Inc., reported on May 26, 2026, that he sold company common stock valued at $1,761. This divestiture was executed following the exercise of stock options, with both actions being carried out under a Rule 10b5-1 trading plan that was initially adopted on February 2, 2026.
Specifically, Mr. Khurram sold 568 shares of common stock. These shares were transacted at a weighted average price of $3.1004 per share. The sale occurred across multiple transactions, with observed prices ranging from $3.00 to $3.01, resulting in the total realized value of $1,761 for the 568 shares.
It is important to note the current market context for Galectin Therapeutics (NASDAQ: GALT). The stock has since experienced a decline to $2.70. This movement reflects broader volatility within the company's equity valuation. While the stock has seen a substantial drop of 53% over the past six months, it concurrently achieved a strong gain of 109% over the preceding year.
Regarding the financial standing and structure of GALT, its current market capitalization is reported at $177.81 million. Furthermore, prior to the recent sale, Mr. Khurram had acquired an additional 568 shares of common stock by exercising options. These options were purchased at a price of $1.23 per share, totaling $698 in value. These specific options formed part of a larger grant that included vesting portions scheduled through December 31, 2026, and carried an expiration date set for January 23, 2035.
Following the sequence of transactions detailed, Mr. Khurram's direct holdings now consist of zero shares of common stock but include 40,057 stock options. Analysis from InvestingPro suggests that GALT may be overvalued at its current price levels, although professional analysts maintain a bullish $11 price target for the equity.
Recent Corporate and Clinical Developments
In parallel to these insider trading activities, Galectin Therapeutics has made several significant announcements regarding its scientific pipeline and corporate governance. The company recently published the results of its NAVIGATE Phase 2b clinical trial in the journal *Hepatology*. This study was designed to evaluate belapectin, which functions as a galectin-3 inhibitor, specifically within patient populations diagnosed with MASH cirrhosis and portal hypertension who did not have esophageal varices at baseline.
The scope of this investigation was global, utilizing a randomized, placebo-controlled trial structure that spanned an 18-month treatment duration. Beyond its clinical research efforts, Galectin Therapeutics also announced the formal appointment of Dr. Henry Brem to serve as an independent director on the company's Board of Directors. Dr. Brem is recognized as a distinguished neurosurgeon affiliated with Johns Hopkins University and possesses a history of holding significant roles within that institution.
Key Takeaways and Market Implications
The combination of insider activity, coupled with positive clinical data releases and board strengthening, provides several points for analysis:
-
Risks
- Stock Volatility and Decline
- Potential Overvaluation Concerns from Analysis Tools
- Reliance on Future Clinical Outcomes for Valuation
More from Insider Trading